Inclusion of stroke in cardiovascular risk prediction instruments: A statement for healthcare professionals from the American Heart Association/American Stroke Association

Daniel T. Lackland, Mitchell S V Elkind, Ralph D'Agostino, Mandip S. Dhamoon, David C. Goff, Randall T. Higashida, Leslie A. McClure, Pamela H. Mitchell, Ralph L Sacco, Cathy A. Sila, Sidney C. Smith, David Tanne, David L. Tirschwell, Emmanuel Touzé, Lawrence R. Wechsler

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Background and Purpose-Current US guideline statements regarding primary and secondary cardiovascular risk prediction and prevention use absolute risk estimates to identify patients who are at high risk for vascular disease events and who may benefit from specific preventive interventions. These guidelines do not explicitly include patients with stroke, however. This statement provides an overview of evidence and arguments supporting (1) the inclusion of patients with stroke, and atherosclerotic stroke in particular, among those considered to be at high absolute risk of cardiovascular disease and (2) the inclusion of stroke as part of the outcome cluster in risk prediction instruments for vascular disease. METHODS AND Results-Writing group members were nominated by the committee co-chairs on the basis of their previous work in relevant topic areas and were approved by the American Heart Association (AHA) Stroke Council's Scientific Statements Oversight Committee and the AHA Manuscript Oversight Committee. The writers used systematic literature reviews (covering the period from January 1980 to March 2010), reference to previously published guidelines, personal files, and expert opinion to summarize existing evidence, indicate gaps in current knowledge, and, when appropriate, formulate recommendations using standard AHA criteria. All members of the writing group had the opportunity to comment on the recommendations and approved the final version of this document. The guideline underwent extensive AHA internal peer review, Stroke Council leadership review, and Scientific Statements Oversight Committee review before consideration and approval by the AHA Science Advisory and Coordinating Committee. There are several reasons to consider stroke patients, and particularly patients with atherosclerotic stroke, among the groups of patients at high absolute risk of coronary and cardiovascular disease. First, evidence suggests that patients with ischemic stroke are at high absolute risk of fatal or nonfatal myocardial infarction or sudden death, approximating the ≥20% absolute risk over 10 years that has been used in some guidelines to define coronary risk equivalents. Second, inclusion of atherosclerotic stroke would be consistent with the reasons for inclusion of diabetes mellitus, peripheral vascular disease, chronic kidney disease, and other atherosclerotic disorders despite an absence of uniformity of evidence of elevated risks across all populations or patients. Third, the large-vessel atherosclerotic subtype of ischemic stroke shares pathophysiological mechanisms with these other disorders. Inclusion of stroke as a high-risk condition could result in an expansion of 10% in the number of patients considered to be at high risk. However, because of the heterogeneity of stroke, it is uncertain whether other stroke subtypes, including hemorrhagic and nonatherosclerotic ischemic stroke subtypes, should be considered to be at the same high levels of risk, and further research is needed. Inclusion of stroke with myocardial infarction and sudden death among the outcome cluster of cardiovascular events in risk prediction instruments, moreover, is appropriate because of the impact of stroke on morbidity and mortality, the similarity of many approaches to prevention of stroke and these other forms of vascular disease, and the importance of stroke relative to coronary disease in some subpopulations. Non-US guidelines often include stroke patients among others at high cardiovascular risk and include stroke as a relevant outcome along with cardiac end points. Conclusions-Patients with atherosclerotic stroke should be included among those deemed to be at high risk (≥20% over 10 years) of further atherosclerotic coronary events. Inclusion of nonatherosclerotic stroke subtypes remains less certain. For the purposes of primary prevention, ischemic stroke should be included among cardiovascular disease outcomes in absolute risk assessment algorithms. The inclusion of atherosclerotic ischemic stroke as a high-risk condition and the inclusion of ischemic stroke more broadly as an outcome will likely have important implications for prevention of cardiovascular disease, because the number of patients considered to be at high risk would grow substantially.

Original languageEnglish
Pages (from-to)1998-2027
Number of pages30
JournalStroke
Volume43
Issue number7
DOIs
StatePublished - Jul 1 2012
Externally publishedYes

Fingerprint

Stroke
Myocardial Infarction
Delivery of Health Care
American Heart Association
Guidelines
Cardiovascular Diseases
Vascular Diseases
Advisory Committees
Sudden Death
Coronary Disease
Peer Review
Peripheral Vascular Diseases
Manuscripts
Expert Testimony
Primary Prevention
Chronic Renal Insufficiency

Keywords

  • AHA Scientific Statements
  • cardiovascular disease
  • risk assessment
  • risk prediction
  • stroke
  • vascular disease

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Clinical Neurology
  • Advanced and Specialized Nursing

Cite this

Lackland, D. T., Elkind, M. S. V., D'Agostino, R., Dhamoon, M. S., Goff, D. C., Higashida, R. T., ... Wechsler, L. R. (2012). Inclusion of stroke in cardiovascular risk prediction instruments: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 43(7), 1998-2027. https://doi.org/10.1161/STR.0b013e31825bcdac

Inclusion of stroke in cardiovascular risk prediction instruments : A statement for healthcare professionals from the American Heart Association/American Stroke Association. / Lackland, Daniel T.; Elkind, Mitchell S V; D'Agostino, Ralph; Dhamoon, Mandip S.; Goff, David C.; Higashida, Randall T.; McClure, Leslie A.; Mitchell, Pamela H.; Sacco, Ralph L; Sila, Cathy A.; Smith, Sidney C.; Tanne, David; Tirschwell, David L.; Touzé, Emmanuel; Wechsler, Lawrence R.

In: Stroke, Vol. 43, No. 7, 01.07.2012, p. 1998-2027.

Research output: Contribution to journalArticle

Lackland, DT, Elkind, MSV, D'Agostino, R, Dhamoon, MS, Goff, DC, Higashida, RT, McClure, LA, Mitchell, PH, Sacco, RL, Sila, CA, Smith, SC, Tanne, D, Tirschwell, DL, Touzé, E & Wechsler, LR 2012, 'Inclusion of stroke in cardiovascular risk prediction instruments: A statement for healthcare professionals from the American Heart Association/American Stroke Association', Stroke, vol. 43, no. 7, pp. 1998-2027. https://doi.org/10.1161/STR.0b013e31825bcdac
Lackland, Daniel T. ; Elkind, Mitchell S V ; D'Agostino, Ralph ; Dhamoon, Mandip S. ; Goff, David C. ; Higashida, Randall T. ; McClure, Leslie A. ; Mitchell, Pamela H. ; Sacco, Ralph L ; Sila, Cathy A. ; Smith, Sidney C. ; Tanne, David ; Tirschwell, David L. ; Touzé, Emmanuel ; Wechsler, Lawrence R. / Inclusion of stroke in cardiovascular risk prediction instruments : A statement for healthcare professionals from the American Heart Association/American Stroke Association. In: Stroke. 2012 ; Vol. 43, No. 7. pp. 1998-2027.
@article{b9001bfee2b54f3db2bc40340a8615ff,
title = "Inclusion of stroke in cardiovascular risk prediction instruments: A statement for healthcare professionals from the American Heart Association/American Stroke Association",
abstract = "Background and Purpose-Current US guideline statements regarding primary and secondary cardiovascular risk prediction and prevention use absolute risk estimates to identify patients who are at high risk for vascular disease events and who may benefit from specific preventive interventions. These guidelines do not explicitly include patients with stroke, however. This statement provides an overview of evidence and arguments supporting (1) the inclusion of patients with stroke, and atherosclerotic stroke in particular, among those considered to be at high absolute risk of cardiovascular disease and (2) the inclusion of stroke as part of the outcome cluster in risk prediction instruments for vascular disease. METHODS AND Results-Writing group members were nominated by the committee co-chairs on the basis of their previous work in relevant topic areas and were approved by the American Heart Association (AHA) Stroke Council's Scientific Statements Oversight Committee and the AHA Manuscript Oversight Committee. The writers used systematic literature reviews (covering the period from January 1980 to March 2010), reference to previously published guidelines, personal files, and expert opinion to summarize existing evidence, indicate gaps in current knowledge, and, when appropriate, formulate recommendations using standard AHA criteria. All members of the writing group had the opportunity to comment on the recommendations and approved the final version of this document. The guideline underwent extensive AHA internal peer review, Stroke Council leadership review, and Scientific Statements Oversight Committee review before consideration and approval by the AHA Science Advisory and Coordinating Committee. There are several reasons to consider stroke patients, and particularly patients with atherosclerotic stroke, among the groups of patients at high absolute risk of coronary and cardiovascular disease. First, evidence suggests that patients with ischemic stroke are at high absolute risk of fatal or nonfatal myocardial infarction or sudden death, approximating the ≥20{\%} absolute risk over 10 years that has been used in some guidelines to define coronary risk equivalents. Second, inclusion of atherosclerotic stroke would be consistent with the reasons for inclusion of diabetes mellitus, peripheral vascular disease, chronic kidney disease, and other atherosclerotic disorders despite an absence of uniformity of evidence of elevated risks across all populations or patients. Third, the large-vessel atherosclerotic subtype of ischemic stroke shares pathophysiological mechanisms with these other disorders. Inclusion of stroke as a high-risk condition could result in an expansion of 10{\%} in the number of patients considered to be at high risk. However, because of the heterogeneity of stroke, it is uncertain whether other stroke subtypes, including hemorrhagic and nonatherosclerotic ischemic stroke subtypes, should be considered to be at the same high levels of risk, and further research is needed. Inclusion of stroke with myocardial infarction and sudden death among the outcome cluster of cardiovascular events in risk prediction instruments, moreover, is appropriate because of the impact of stroke on morbidity and mortality, the similarity of many approaches to prevention of stroke and these other forms of vascular disease, and the importance of stroke relative to coronary disease in some subpopulations. Non-US guidelines often include stroke patients among others at high cardiovascular risk and include stroke as a relevant outcome along with cardiac end points. Conclusions-Patients with atherosclerotic stroke should be included among those deemed to be at high risk (≥20{\%} over 10 years) of further atherosclerotic coronary events. Inclusion of nonatherosclerotic stroke subtypes remains less certain. For the purposes of primary prevention, ischemic stroke should be included among cardiovascular disease outcomes in absolute risk assessment algorithms. The inclusion of atherosclerotic ischemic stroke as a high-risk condition and the inclusion of ischemic stroke more broadly as an outcome will likely have important implications for prevention of cardiovascular disease, because the number of patients considered to be at high risk would grow substantially.",
keywords = "AHA Scientific Statements, cardiovascular disease, risk assessment, risk prediction, stroke, vascular disease",
author = "Lackland, {Daniel T.} and Elkind, {Mitchell S V} and Ralph D'Agostino and Dhamoon, {Mandip S.} and Goff, {David C.} and Higashida, {Randall T.} and McClure, {Leslie A.} and Mitchell, {Pamela H.} and Sacco, {Ralph L} and Sila, {Cathy A.} and Smith, {Sidney C.} and David Tanne and Tirschwell, {David L.} and Emmanuel Touz{\'e} and Wechsler, {Lawrence R.}",
year = "2012",
month = "7",
day = "1",
doi = "10.1161/STR.0b013e31825bcdac",
language = "English",
volume = "43",
pages = "1998--2027",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Inclusion of stroke in cardiovascular risk prediction instruments

T2 - A statement for healthcare professionals from the American Heart Association/American Stroke Association

AU - Lackland, Daniel T.

AU - Elkind, Mitchell S V

AU - D'Agostino, Ralph

AU - Dhamoon, Mandip S.

AU - Goff, David C.

AU - Higashida, Randall T.

AU - McClure, Leslie A.

AU - Mitchell, Pamela H.

AU - Sacco, Ralph L

AU - Sila, Cathy A.

AU - Smith, Sidney C.

AU - Tanne, David

AU - Tirschwell, David L.

AU - Touzé, Emmanuel

AU - Wechsler, Lawrence R.

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Background and Purpose-Current US guideline statements regarding primary and secondary cardiovascular risk prediction and prevention use absolute risk estimates to identify patients who are at high risk for vascular disease events and who may benefit from specific preventive interventions. These guidelines do not explicitly include patients with stroke, however. This statement provides an overview of evidence and arguments supporting (1) the inclusion of patients with stroke, and atherosclerotic stroke in particular, among those considered to be at high absolute risk of cardiovascular disease and (2) the inclusion of stroke as part of the outcome cluster in risk prediction instruments for vascular disease. METHODS AND Results-Writing group members were nominated by the committee co-chairs on the basis of their previous work in relevant topic areas and were approved by the American Heart Association (AHA) Stroke Council's Scientific Statements Oversight Committee and the AHA Manuscript Oversight Committee. The writers used systematic literature reviews (covering the period from January 1980 to March 2010), reference to previously published guidelines, personal files, and expert opinion to summarize existing evidence, indicate gaps in current knowledge, and, when appropriate, formulate recommendations using standard AHA criteria. All members of the writing group had the opportunity to comment on the recommendations and approved the final version of this document. The guideline underwent extensive AHA internal peer review, Stroke Council leadership review, and Scientific Statements Oversight Committee review before consideration and approval by the AHA Science Advisory and Coordinating Committee. There are several reasons to consider stroke patients, and particularly patients with atherosclerotic stroke, among the groups of patients at high absolute risk of coronary and cardiovascular disease. First, evidence suggests that patients with ischemic stroke are at high absolute risk of fatal or nonfatal myocardial infarction or sudden death, approximating the ≥20% absolute risk over 10 years that has been used in some guidelines to define coronary risk equivalents. Second, inclusion of atherosclerotic stroke would be consistent with the reasons for inclusion of diabetes mellitus, peripheral vascular disease, chronic kidney disease, and other atherosclerotic disorders despite an absence of uniformity of evidence of elevated risks across all populations or patients. Third, the large-vessel atherosclerotic subtype of ischemic stroke shares pathophysiological mechanisms with these other disorders. Inclusion of stroke as a high-risk condition could result in an expansion of 10% in the number of patients considered to be at high risk. However, because of the heterogeneity of stroke, it is uncertain whether other stroke subtypes, including hemorrhagic and nonatherosclerotic ischemic stroke subtypes, should be considered to be at the same high levels of risk, and further research is needed. Inclusion of stroke with myocardial infarction and sudden death among the outcome cluster of cardiovascular events in risk prediction instruments, moreover, is appropriate because of the impact of stroke on morbidity and mortality, the similarity of many approaches to prevention of stroke and these other forms of vascular disease, and the importance of stroke relative to coronary disease in some subpopulations. Non-US guidelines often include stroke patients among others at high cardiovascular risk and include stroke as a relevant outcome along with cardiac end points. Conclusions-Patients with atherosclerotic stroke should be included among those deemed to be at high risk (≥20% over 10 years) of further atherosclerotic coronary events. Inclusion of nonatherosclerotic stroke subtypes remains less certain. For the purposes of primary prevention, ischemic stroke should be included among cardiovascular disease outcomes in absolute risk assessment algorithms. The inclusion of atherosclerotic ischemic stroke as a high-risk condition and the inclusion of ischemic stroke more broadly as an outcome will likely have important implications for prevention of cardiovascular disease, because the number of patients considered to be at high risk would grow substantially.

AB - Background and Purpose-Current US guideline statements regarding primary and secondary cardiovascular risk prediction and prevention use absolute risk estimates to identify patients who are at high risk for vascular disease events and who may benefit from specific preventive interventions. These guidelines do not explicitly include patients with stroke, however. This statement provides an overview of evidence and arguments supporting (1) the inclusion of patients with stroke, and atherosclerotic stroke in particular, among those considered to be at high absolute risk of cardiovascular disease and (2) the inclusion of stroke as part of the outcome cluster in risk prediction instruments for vascular disease. METHODS AND Results-Writing group members were nominated by the committee co-chairs on the basis of their previous work in relevant topic areas and were approved by the American Heart Association (AHA) Stroke Council's Scientific Statements Oversight Committee and the AHA Manuscript Oversight Committee. The writers used systematic literature reviews (covering the period from January 1980 to March 2010), reference to previously published guidelines, personal files, and expert opinion to summarize existing evidence, indicate gaps in current knowledge, and, when appropriate, formulate recommendations using standard AHA criteria. All members of the writing group had the opportunity to comment on the recommendations and approved the final version of this document. The guideline underwent extensive AHA internal peer review, Stroke Council leadership review, and Scientific Statements Oversight Committee review before consideration and approval by the AHA Science Advisory and Coordinating Committee. There are several reasons to consider stroke patients, and particularly patients with atherosclerotic stroke, among the groups of patients at high absolute risk of coronary and cardiovascular disease. First, evidence suggests that patients with ischemic stroke are at high absolute risk of fatal or nonfatal myocardial infarction or sudden death, approximating the ≥20% absolute risk over 10 years that has been used in some guidelines to define coronary risk equivalents. Second, inclusion of atherosclerotic stroke would be consistent with the reasons for inclusion of diabetes mellitus, peripheral vascular disease, chronic kidney disease, and other atherosclerotic disorders despite an absence of uniformity of evidence of elevated risks across all populations or patients. Third, the large-vessel atherosclerotic subtype of ischemic stroke shares pathophysiological mechanisms with these other disorders. Inclusion of stroke as a high-risk condition could result in an expansion of 10% in the number of patients considered to be at high risk. However, because of the heterogeneity of stroke, it is uncertain whether other stroke subtypes, including hemorrhagic and nonatherosclerotic ischemic stroke subtypes, should be considered to be at the same high levels of risk, and further research is needed. Inclusion of stroke with myocardial infarction and sudden death among the outcome cluster of cardiovascular events in risk prediction instruments, moreover, is appropriate because of the impact of stroke on morbidity and mortality, the similarity of many approaches to prevention of stroke and these other forms of vascular disease, and the importance of stroke relative to coronary disease in some subpopulations. Non-US guidelines often include stroke patients among others at high cardiovascular risk and include stroke as a relevant outcome along with cardiac end points. Conclusions-Patients with atherosclerotic stroke should be included among those deemed to be at high risk (≥20% over 10 years) of further atherosclerotic coronary events. Inclusion of nonatherosclerotic stroke subtypes remains less certain. For the purposes of primary prevention, ischemic stroke should be included among cardiovascular disease outcomes in absolute risk assessment algorithms. The inclusion of atherosclerotic ischemic stroke as a high-risk condition and the inclusion of ischemic stroke more broadly as an outcome will likely have important implications for prevention of cardiovascular disease, because the number of patients considered to be at high risk would grow substantially.

KW - AHA Scientific Statements

KW - cardiovascular disease

KW - risk assessment

KW - risk prediction

KW - stroke

KW - vascular disease

UR - http://www.scopus.com/inward/record.url?scp=84863307051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863307051&partnerID=8YFLogxK

U2 - 10.1161/STR.0b013e31825bcdac

DO - 10.1161/STR.0b013e31825bcdac

M3 - Article

C2 - 22627990

AN - SCOPUS:84863307051

VL - 43

SP - 1998

EP - 2027

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 7

ER -